Table 1: Characteristics of included trials (two-armed parallel group).

AuthorNumber of patientsIntervention
ExperimentalControlExperimentalControl Duration (wks) Outcomes

Liu and Hu 2008 [12] 3030LM, Ber, MetLM + Met8 FBG, PPG, HbA1c, FINS
Li 2008 [32]3332LM, BerLM + Met12FBG, PPG, HbA1c, FINS, TC, TG, LDL-C, HDL-C
Wang 2008 [14]3031LM, BerLM12 FBG, PPG, HbA1c, FINS, TC, TG, LDL-C, HDL-C, AE
Zhang et al. 2008 [9]5852LM, BerPlacebo, LM12FBG, PPG, HbA1c, FINS, TC, TG, LDL-C, HDL-C, AE
Yin et al. 2008 [10]1516LM, BerMet, LM13FBG, PPG, HbA1c, FINS, TC, TG, LDL-C, HDL-C, AE
Sheng and Xie 2010 [15]3030Ber, Met, GlipMet, Glip 12FBG, FINS, AE
Ye 2010 [16]4040Ber, Met, GlimMet, Glim12FBG, PPG, HbA1c, TC, TG, LDL-C, HDL-C, AE
Zhang et al. 2011 [17]3030LM, BerLM, Ber, Ros12FBG, HbA1c, TC, TG, LDL-C, HDL-C
Yin et al. 2011 [18]3030LM, Ber, MetLM, Met24FBG, PPG, HbA1c, FINS, TC, TG, LDL-C, HDL-C, AE

Note: AE: adverse effect; Ber: berberine; Glim: glimepiride; Glip: glipizide; LM: lifestyle modification; Met: metformin; Ros: rosiglitazone.